Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 4/2018

01-08-2018 | The Global Epidemic (SH Vermund, Section Editor)

Federal Response to the Opioid Crisis

Authors: Kimberly Johnson, Chris Jones, Wilson Compton, Grant Baldwin, Jennifer Fan, Jonathan Mermin, Jean Bennett

Published in: Current HIV/AIDS Reports | Issue 4/2018

Login to get access

Abstract

Purpose of Review

In light of the current crisis in opioid involved overdose deaths, the federal Department of Health and Human Services operating divisions are working together to implement a data-driven, research-based strategy to reduce opioid misuse and its consequences.

Recent Findings

The strategy has five elements: (1) strengthening public health data collection and reporting; (2) advancing the practice of pain management; (3) improving access to addiction prevention, treatment, and recovery support services; (4) increasing availability of overdose-reversing drugs; and (5) supporting cutting-edge research in treatment of pain, opioid use disorder, and associated conditions.

Summary

The Department of Health and Human Services has developed a concerted, coordinated evidence-based effort across department divisions to reduce opioid misuse, prevalence of opioid use disorder, and reduce deaths due to opioid use.
Literature
1.
•• Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health (HHS Publication No. SMA 17-5044, NSDUH Series H-52). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. 2017. Retrieved from https://​www.​samhsa.​gov/​data/​. Current epidemiologic data on opioid use, use disorder, and associated conditions.
2.
3.
• Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, et al. The effectiveness and risks of long-term opioid therapy for chronic pain. Annals of Internal Medicine. 2015;162(4):276–86. Evidence of poor outcomes for use of opioids for chronic pain CrossRefPubMed
4.
Wu LT, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016 Dec 1;169:117–27.CrossRefPubMedPubMedCentral
5.
Ronan MV, Herzig SJ. Hospitalizations related to opioid abuse/dependence and associated serious infections increased sharply, 2002–12. Health Aff. 2016 May 1;35(5):832–7.CrossRef
6.
Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin Infect Dis. 2014 Aug 11;59(10):1411–9.CrossRefPubMed
7.
• Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian L, Serrecchia J, Blankenship S, Ward JW, Holtzman D. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤ 30 years-Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR. Morb Mortal Wkly Rep 2015 May;64(17):453–458.
8.
• Wejnert C. Vital signs: trends in HIV diagnoses, risk behaviors, and prevention among persons who inject drugs—United States. MMWR. Morbidity and mortality weekly report. 2016; 65. Information on linkages between HIV trends and opioid use.
9.
Peters PJ, Pontones P, Hoover KW, Patel MR, Galang RR, Shields J, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014–2015. N Engl J Med. 2016 Jul 21;375(3):229–39.CrossRefPubMed
10.
11.
12.
13.
14.
Warner, M., Trinidad, J.P., Bastian, B.A., Miniño, A.M. and Hedegaard, H., 2016. Drugs most frequently involved in drug overdose deaths: United States, 2010-2014. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System, 65(10), pp.1–15.
15.
16.
17.
Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016 Apr 19;315(15):1624–45.CrossRefPubMed
18.
19.
Spoth R, Trudeau L, Shin C, Ralston E, Redmond C, Greenberg M, et al. Longitudinal effects of universal preventive intervention on prescription drug misuse: three randomized controlled trials with late adolescents and young adults. AJPH. 2013;103:665–72.CrossRef
20.
McAfee T, Davis KC, Alexander RL, Pechacek TF, Bunnell R. Effect of the first federally funded US antismoking national media campaign. Lancet. 2013;382(9909):2003–11.CrossRefPubMed
21.
Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015 Mar 1;23(2):63–75.CrossRefPubMed
22.
•• Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health (ajph). 2015 Aug 3;105:e55–63.CrossRef
23.
Stein BD, Sorbero M, Dick AW, Pacula RL, Burns RM, Gordon AJ. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211–2.CrossRefPubMedPubMedCentral
24.
Huhn AS, Dunn KE. Why aren't physicians prescribing more buprenorphine? J Subst Abus Treat. 2017 Jul 31;78:1–7.CrossRef
25.
Yancovitz SR, Des Jarlais DC, Peyser NP, Drew E, Friedmann P, Trigg HL, et al. A randomized trial of an interim methadone maintenance clinic. Am J Public Health. 1991 Sep;81(9):1185–91.CrossRefPubMedPubMedCentral
26.
Schwartz RP, Highfield DA, Jaffe JH, Brady JV, Butler CB, Rouse CO, et al. A randomized controlled trial of interim methadone maintenance. Arch Gen Psychiatry. 2006;63(1):102–9.CrossRefPubMed
27.
Sigmon SC, Ochalek TA, Meyer AC, Hruska B, Heil SH, Badger GJ, et al. Interim buprenorphine vs. waiting list for opioid dependence. N Engl J Med. 2016 Dec 22;375(25):2504–5.CrossRefPubMedPubMedCentral
28.
Compton WM, Volkow ND. Major increases in opioid analgesic abuse: concerns and strategies. Drug Alcohol Depend. 2006;81(2):103–7.CrossRefPubMed
29.
Compton WM, Jones CM, Baldwin GT. Understanding the relationship between prescription opioid and heroin abuse. N Engl J Med. 2016;374:154–63.CrossRefPubMed
30.
Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68:1238–46.CrossRefPubMedPubMedCentral
31.
Hser YI, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction. 2016 Apr 1;111(4):695–705.CrossRefPubMedPubMedCentral
32.
Weiss RD, Rao V. The prescription opioid addiction treatment study: what have we learned. Drug Alcohol Depend. 2017 Apr 1;173:S48–54.CrossRefPubMed
33.
Weiss RD, Potter JS, Griffin ML, Provost SE, Fitzmaurice GM, McDermott KA, et al. Long-term outcomes from the national drug abuse treatment clinical trials network prescription opioid addiction treatment study. Drug Alcohol Depend. 2015 May 1;150:112–9.CrossRefPubMedPubMedCentral
34.
Bassuk EL, Hanson J, Greene RN, Richard M, Laudet A. Peer-delivered recovery support services for addictions in the United States: a systematic review. J Subst Abus Treat. 2016 Apr 30;63:1–9.CrossRef
35.
21st Century Cures Act, H.R. 34, 114th Cong. 2015.
36.
Hagan J, McGough JP, Thiede J, Hopkins S, Duchin J, Alexander ER. Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors. J Subst Abuse Treat. 2000;19:247–52.CrossRefPubMed
37.
Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013;57(S2):S39–45.CrossRefPubMedPubMedCentral
38.
Sypsa V, Psichogiou M, Paraskevis D, Nikolopoulos G, Tsiara C, Paraskeva D, et al. Rapid decline in HIV incidence among persons who inject drugs during a fast-track combination prevention program after an HIV outbreak in Athens. J. Infect Dis. 2017;215(10):1496–505.
39.
Dahari H, Boodram B. How to eliminate HCV in people who inject drugs in the USA. The Lancet Infectious Diseases. Available on-line: https://​doi.​org/​10.​1016/​S1473-3099(17)30678-3 Accessed November 21, 2017.
40.
Grebely J, Matthews GV, Lloyd AR, Dore GJ. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention. Clin Infect Dis. 2013;57(7):1014–20.CrossRefPubMed
41.
Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Hagan H, Beatrice S, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990–2001. AIDS. 2005 Oct 1;19:S20–5.CrossRefPubMed
42.
43.
•• Wood E. How Drug Policy Should Respond to the HIV Epidemic. Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), Vancouver, Canada, presentation TUPL0103, 2015. Policy recommendations for addressing the HIV epidemic through addressing the opioid epidemic.
44.
Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health. 2017; https://​doi.​org/​10.​1016/​S2214-109X(17)30373-X.
45.
46.
Metsch LR, Feaster DJ, Gooden L, Matheson T, Mandler RN, Haynes L, et al. Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. Am J Public Health. 2012;102(6):1160–7.CrossRefPubMedPubMedCentral
47.
Metsch LR, Feaster DJ, Gooden L, Schackman BR, Matheson T, Das M, et al. Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the AWARE randomized clinical trial. JAMA. 2013;310(16):1701–10.CrossRefPubMedPubMedCentral
48.
Metsch LR, Feaster DJ, Gooden L, Matheson T, Stitzer M, Das M, et al. Effect of patient navigation with or without financial incentives on viral suppression among hospitalized patients with HIV infection and substance use: a randomized clinical trial. JAMA. 2016 Jul 12;316(2):156–70.CrossRefPubMedPubMedCentral
49.
Conrad C, Bradley HM, Broz D, Buddha S, Chapman EL, Galang RR, et al. Community outbreak of HIV infection linked to injection drug use of oxymorphone—Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015 May 1;64(16):443–4.PubMedPubMedCentral
50.
51.
52.
Crist RC, Doyle GA, Nelson EC, Degenhardt L, Martin NG, Montgomery GW, Saxon AJ, Ling W, Berrettini WH. A polymorphism in the OPRM1 3′-untranslated region is associated with methadone efficacy in treating opioid dependence. Pharmacogenomics J 2016 Dec 13.
Metadata
Title
Federal Response to the Opioid Crisis
Authors
Kimberly Johnson
Chris Jones
Wilson Compton
Grant Baldwin
Jennifer Fan
Jonathan Mermin
Jean Bennett
Publication date
01-08-2018
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 4/2018
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-018-0398-8

Other articles of this Issue 4/2018

Current HIV/AIDS Reports 4/2018 Go to the issue

The Global Epidemic (SH Vermund, Section Editor)

Implementing Treatment of Opioid-Use Disorder in Rural Settings: a Focus on HIV and Hepatitis C Prevention and Treatment

The Global Epidemic (SH Vermund, Section Editor)

Young Drug Users: a Vulnerable Population and an Underutilized Resource in HIV/HCV Prevention

HIV and Technology (J Simoni and K Horvath, Section Editors)

eHealth to Enhance Treatment Adherence Among Youth Living with HIV

The Global Epidemic (SH Vermund, Section Editor)

HIV/HCV Co-infection: Burden of Disease and Care Strategies in Appalachia

HIV and Technology (J Simoni and K Horvath, Section Editors)

eHealth and Prevention of Mother-to-Child Transmission of HIV

The Global Epidemic (SH Vermund, Section Editor)

Working With Persons Who Inject Drugs and Live in Rural Areas: Implications From China/Vietnam for the USA
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits